Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma

• Published in: Clinical cancer research Vol. 25; no. 24; pp. 7424 - 7435
• Main Authors: Thakur, Rohit, Laye, Jonathan P., Lauss, Martin, Diaz, Joey Mark S., O'Shea, Sally Jane, Poźniak, Joanna, Filia, Anastasia, Harland, Mark, Gascoyne, Joanne, Randerson-Moor, Juliette A., Chan, May, Mell, Tracey, Jönsson, Göran, Bishop, D. Timothy, Newton-Bishop, Julia, Barrett, Jennifer H., Nsengimana, Jérémie
• Format: Journal Article
• Language: English
• Published: United States 15.12.2019
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - genetics; Cancer and Oncology; Cancer och onkologi; Clinical Medicine; Cohort Studies; Computational Biology - methods; Female; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy - mortality; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Melanoma - genetics; Melanoma - pathology; Melanoma - therapy; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Staging; Skin Neoplasms - genetics; Skin Neoplasms - pathology; Skin Neoplasms - therapy; Survival Rate; Transcriptome; Treatment Outcome; Young Adult

Previously identified transcriptomic signatures have been based on primary and metastatic melanomas with relatively few American Joint Committee on Cancer (AJCC) stage I tumors, given difficulties in sampling small tumors. The advent of adjuvant therapies has highlighted the need for better prognost...